
Ash 2020 preview – Novartis touts its Tasigna follow-on
Pivotal data at the upcoming Ash conference make Novartis’s asciminib one of the highlights for oncology watchers.
Pivotal data at the upcoming Ash conference make Novartis’s asciminib one of the highlights for oncology watchers.